相关实验视频

Updated: Jun 21, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

受体氨酸激酶类孤儿受体是癌症免疫治疗中的潜在标

Jiaqi Wang¹, Zhoufang Li², Qi Zhao^1,3

¹Cancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR 999078, China.

Journal of leukocyte biology

|July 8, 2024

概括

受体氨酸激酶类孤儿受体 (ROR1和ROR2) 在发育过程中至关重要,但在癌症中过度表达. 准ROR为癌症免疫治疗提供了一个有希望的策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
免疫学免疫学免疫学

背景情况:

受体氨酸激酶类孤儿受体 (ROR),包括ROR1和ROR2,在胚胎发育过程中至关重要.
ROR蛋白通常在成年组织中以低水平表达,但在各种血液性恶性瘤和固体瘤中显著过度表达.
ROR信号与细胞生存,极性和迁移等基本细胞过程有关,使其成为瘤发生的关键参与者.

研究的目的:

审查ROR在发育形态发生过程中的表达和结构特征.
阐明ROR在癌症中的作用,特别是与Wnt5a信号通路有关.
突出针对ROR的当前和新兴癌症免疫疗法策略.

主要方法:

对ROR表达,结构和功能研究的文献综述.
对ROR参与胚胎发育和癌症的分析.
检查与癌症中ROR相关的Wnt5a信号通路.
对针对ROR的癌症免疫疗法的临床前和临床数据的审查.

主要成果:

ROR蛋白在胚胎发育和组织模式中起着至关重要的作用.
异常ROR表达是众多癌症的标志,与疾病进展和不良预后相关.
ROR信号,通常与Wnt5a结合,促进瘤细胞的存活,入侵和转移.
一些针对ROR的免疫疗法,包括单克隆抗体和CAR-T细胞,正在研究中,并显示出治疗潜力.

结论:

ROR受体是发育和瘤发生的关键调节者.
癌症中ROR过度表达具有显著的治疗脆弱性.
针对ROR,特别是与Wnt5a通路调节相结合,有望为有效的癌症免疫疗法策略提供希望.

关键词:

抗体药物联合体 (ADCs) 是一种抗体药物联合体.癌症免疫疗法免疫疗法仿制性抗原受体T细胞 (CAR-T)单克隆抗体 (mAbs) 是一种单克隆抗体.类似于受体氨酸激酶的孤儿受体 (ROR1和ROR2)

更多相关视频

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

相关概念视频

Receptor Tyrosine Kinases

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...